Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
19#iSCLife-POI
- Development stage
- Unknown
- Lead developer
- Sclnow Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
19#iSCLife-POI is a cell-based biologic therapy developed by Sclnow Biotechnology Co., Ltd. for the treatment of Premature Ovarian Insufficiency (POI). The therapy utilizes human umbilical cord mesenchymal stem cells (hucMSCs), which are multipotent stromal cells capable of migrating to damaged ovarian tissue. Once at the site, these cells exert therapeutic effects by reducing oxidative stress, inhibiting apoptosis of granulosa cells, and promoting the regeneration of ovarian follicles. This regenerative approach aims to restore ovarian function and fertility in women under 40 who have experienced early loss of ovarian activity. The product is currently being evaluated in Phase 2 clinical trials to assess its safety and efficacy compared to standard hormone replacement therapy.
- Brand names
- 19#iSCLife-POI
- Other names
- human umbilical cord mesenchymal stem cellshuman umbilical cord mesenchymal stem cells-Sclnow Biotechnology Co., Ltd.-Premature Ovarian Insufficiency
Beyond the preview
Go deeper on 19#iSCLife-POI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 19#iSCLife-POI.